Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
11.64
-0.20 (-1.69%)
At close: Jun 27, 2025, 4:00 PM
11.42
-0.22 (-1.89%)
After-hours: Jun 27, 2025, 5:25 PM EDT
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$197,262
Profits / Employee
-$728,678
Market Cap
887.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NRIX News
- 14 days ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) - GlobeNewsWire
- 22 days ago - Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - GlobeNewsWire
- 26 days ago - Sanofi Exercises License Extension Option to Nurix's STAT6 Program - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewsWire